Cell Reports (Oct 2013)

Expression of BCR/ABL p210 from a Knockin Allele Enhances Bone Marrow Engraftment without Inducing Neoplasia

  • Samantha B. Foley,
  • Zacariah L. Hildenbrand,
  • Abigail A. Soyombo,
  • Jeffery A. Magee,
  • Yipin Wu,
  • Katherine I. Oravecz-Wilson,
  • Theodora S. Ross

DOI
https://doi.org/10.1016/j.celrep.2013.08.037
Journal volume & issue
Vol. 5, no. 1
pp. 51 – 60

Abstract

Read online

Chronic myeloid leukemia (CML) and some acute lymphoblastic leukemias are characterized by the t(9;22) chromosome, which encodes the BCR/ABL oncogene. Multiple mouse models of CML express BCR/ABL at high levels from non-Bcr promoters, resulting in the development of leukemias. In contrast, a significant fraction of healthy humans have been found to have BCR/ABL-positive hematopoietic cells. To bridge the gap between the information derived from current mouse models and nonleukemic humans with the BCR/ABL oncogene, we generated a knockin model with BCR/ABL p210 expressed from the Bcr locus. Unlike previous models, expression of BCR/ABL from the knockin allele did not induce leukemia. BCR/ABL mutant cells did exhibit favorable bone marrow engraftment compared to control cells. These data suggest that BCR/ABL expression alone is insufficient to induce disease. This model allows for inducible spatial and temporal control of BCR/ABL expression for analysis of early steps in the pathogenesis of BCR/ABL-expressing leukemias.